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African green monkey (AGM) tripartite motif protein (TRIM) 5α can inhibit both human immunodeficiency virus type 1 (HIV-1) and simian
immunodeficiency virus SIVmac, whereas cynomolgus monkey (CM) TRIM5α can inhibit HIV-1, but not SIVmac. We previously reported that
the 17-amino-acid region and an adjacent 20-amino-acid duplication in the SPRY(B30.2) domain of AGM TRIM5α determined the species
specificity. In the present study, we demonstrated that CM TRIM5α had a dominant-negative effect on the anti-SIVmac activity of AGM
TRIM5α. In contrast, mutant TRIM5αs lacking the 20-amino-acid duplication did not have the dominant-negative effect, even though they failed
to restrict SIVmac. These results indicated that oligomerization of the SPRY domain is required for anti-SIVmac activity and suggest that tight
interaction between the viral capsid and all three molecules in one TRIM5α trimer may not be necessary for restriction activity.
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monkeyIntroduction
Human immunodeficiency virus type 1 (HIV-1) efficiently
enters cells of OldWorld monkeys but encounters a block before
reverse transcription (Himathongkham and Luciw, 1996;
Hofmann et al., 1999; Shibata et al., 1995). This restriction is
mediated by a dominant-repressive factor, tripartite motif protein
(TRIM) 5α (Stremlau et al., 2004). Rhesus and cynomolgus
monkey (CM) TRIM5α restricted HIV-1 infection (Nakayama et
al., 2005), whereas human TRIM5α restricts N-tropic murine
leukemia virus (N-MLV) infection (Hatziioannou et al., 2004;
Keckesova et al., 2004; Perron et al., 2004; Yap et al., 2004).
African green monkey (AGM) TRIM5α restricts simian immu-
nodeficiency virus SIVmac, human immunodeficiency virus
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doi:10.1016/j.virol.2006.03.035to HIV-1 infection (Hatziioannou et al., 2004; Keckesova et al.,
2004; Nakayama et al., 2005). TRIM5α shares a common
amino-terminal TRIM motif, comprising RING, B-box, and
coiled-coil domains, with other splicing variants, and encodes a
unique SPRY (B30.2) domain (Reymond et al., 2001). Several
recombinant studies between human and rhesus monkey
TRIM5α revealed that the determinant of the species specificity
lies in the SPRY (B30.2) domain of TRIM5α (Perez-Caballero
et al., 2005; Sawyer et al., 2005; Stremlau et al., 2005; Yap et
al., 2005). We also previously demonstrated that 17-amino-acid
residues and the adjacent AGM-specific 20-amino-acid dupli-
cation in the SPRY domain determined species-specific restric-
tion of SIVmac (Nakayama et al., 2005). Owl monkey TRIM5
is fused with cyclophilin A (cypA) within the SPRY domain and
has strong anti-HIV-1 activity (Nisole et al., 2004; Sayah et al.,
2004). Structural predictions suggested that the coiled-coil
domain exhibits a propensity to form oligomers. It was first
reported that rhesus TRIM5γ, a splice variant lacking SPRY
(B30.2) domain, had a dominant-negative effect on HIV-1 res-
triction activity of rhesus TRIM5α (Stremlau et al., 2004).
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monkey TRIM5α or owl monkey TRIM5-cypA in human cells
interferes with the anti-N-MLV activity of endogenous humanFig. 1. (A) Schematic representation of chimeric tripartite motif protein (TRIM) 5α
variable region of the SPRY (B30.2) domain of CV1 and HSC-F TRIM5αs is shown
amino-acid duplication. Filled and open bars denote CV1 and HSC-F sequences, res
and − on the column of inhibition denote full and no suppression, respectively. + and
negative effect on anti-SIVmac activity of CV1-TRIM5α, respectively. Anti-human i
previously (Nakayama et al., 2005). (B) MT4 cells infected with 10 plaque-forming un
tagged version of CV1-TRIM5α-tag (closed squares), HSC-F-TRIM5α-tag (open s
delete-tag (open circles), or HSC-F +60tag (closed triangles) were challenged with sim
for levels of p27. The representative results of three independent experiments with sim
cell of an SeVexpressing CV1-TRIMα-tag and 5 plaque-forming unit per cell of an S
CV1-delete-tag (closed circles), HSC-delete-tag (open circles), or HSC-F +60tag (clo
assayed for levels of p27. The representative result of three independent experiments
TRIM5α proteins. MT4 cells were infected with SeVs expressing the indicated TRIM
to 5). In cases 2 recombinant SeVs were simultaneously infected, 5 plaque-forming u
infection, cells were lysed and immunoprecipitated by an anti-HA antibody. A closed
duplication. An open triangle indicates an HA-tagged HSC-F-TRIM5α (lanes 2 and 6
and 9), lacking the 20-amino-acid duplication.TRIM5α (Berthoux et al., 2005). Here, we show that CM
TRIM5α lacking anti-SIVmac activity had a dominant-negative
effect on the anti-SIVmac activity of AGM TRIM5α.and summary of the results. Alignment of amino-acid sequences of the highly
on the top. Boxes in amino-acid sequence denote the CV1-TRIM5α-specific 20-
pectively. “D” denotes the CV1-TRIM5α-specific 20-amino-acid duplication. +
− on the column of interference denote presence and absence of the dominant-
mmunodeficiency virus type 1 (HIV-1) activity of those TRIM5αs was reported
its per cell of a recombinant Sendai virus (SeV) expressing hemagglutinin (HA)-
quares), CV1-60tag (open triangles), CV1-delete-tag (closed circles), HSC-F-
ian immunodeficiency virus SIVmac239, and culture supernatants were assayed
ilar results are shown. (C) MT4 cells co-infected with 5 plaque-forming unit per
eVexpressing HSC-F-TRIM5α-tag (open squares), CV1-60tag (open triangles),
sed triangles) were challenged with SIVmac239, and culture supernatants were
with similar results is shown. (D) Comparison of expression levels of HA-tagged
5α protein at a multiplicity of infection of 10 plaque-forming unit per cell (lanes 1
nits per cell of each SeV were inoculated (lanes 6 to 9). Twelve hours after SeV
triangle indicates HA-tagged CV1-TRIM5α, which contained the 20-amino-acid
), CV1-60 (lanes 3 and 7), CV1-delete (lanes 4 and 8), and HSC-F-delete (lanes 5
Fig. 2. A single round replication assay. CD4-negative human cell line HeLa
was infected with an SeV expressing indicated TRIM5α at a multiplicity of
infection of 10 plaque-forming unit per cell (columns 1, 3, 5, 7, and 9) and
challenged with vesicular stomatitis virus glycoprotein-pseudotyped SIV-
mac239. In cases 2 recombinant SeVs were simultaneously infected, 5
plaque-forming units per cell of each SeV were inoculated (columns 2, 4, 6,
and 8). Three days after infection, culture supernatants were assayed for levels of
p27. Bars show actual fluctuations of duplicate samples.
160 E.E. Nakayama et al. / Virology 350 (2006) 158–163Results
Among Old World monkey cells, an AGM kidney cell line
CV1 is resistant to not only HIV-1, but also simian immuno-
deficiency virus SIVmac. TRIM5α cDNA of CV1 and HSC-F
cells, a T cell line from a CM, were cloned into Sendai virus
vectors (SeVs). As described previously (Nakayama et al.,
2005), both CV1- and HSC-F-TRIM5αs inhibited HIV-1 infec-
tion (Fig. 1A). CV1-TRIM5α could also inhibit SIVmac in-
fection, whereas HSC-F-TRIM5α could not (Figs. 1A, B). A
comparison of the CV1 and HSC-F TRIM5α sequences showed
the presence of a highly variable region in the N-terminal portion
of the SPRY domain. In this region, CV1-TRIM5α had a 20-
amino-acid duplication, which was totally absent in HSC-F-
TRIM5α (Fig. 1A). We constructed chimeric TRIM5αs from
hemagglutinin (HA)-tagged version of HSC-F-TRIM5α and
CV1-TRIM5α by using SphI and BamHI restriction enzyme
digestion (Fig. 1A). HSC-F +60tag contained the 242 bp SphI–
BamHI fragment of CV1-TRIM5α in the background of HA-
tagged version of HSC-F-TRIM5α. The reciprocal chimera,
CV1-60tag, contained a corresponding 182 bp fragment of HSC-
F-TRIM5α in the background of HA-tagged version of CV1-
TRIM5α. In this SphI–BamHI fragment, the differences bet-
ween CV1 and HSC-F TRIM5α were located in a small region
of 37-amino-acid residues including CV1-specific 20-amino-
acid duplication and adjacent 17-amino-acid residues. In CV1-
delete-tag, CV1-specific 20-amino-acid duplication was deleted
by PCR mutagenesis. In HSC-F-delete-tag, the SphI–BamHI
fragment of HSC-F-TRIM5αwas replaced with the correspond-
ing fragment of CV1-delete-tag. As shown in Fig. 1B, HSC-F
+60tag, the chimeric TRIM5α containing 37-amino-acid resi-
dues from CV1-TRIM5α in the background of HSC-F-TRIM5α
fully acquired the ability to inhibit SIVmac infection. Converse-
ly, all the chimeric TRIM5αs lacking the CV1-specific 20-
amino-acid duplication (CV1-60tag, CV1-delete-tag, and HSC-
F-delete-tag) failed to restrict SIVmac infection (Figs. 1A, B).
All the mutant TRIM5αs described above showed potent anti-
HIV-1 activity as described previously (Fig. 1A) (Nakayama et
al., 2005).
In the present study, we examined whether or not simulta-
neous expression of HSC-F-TRIM5α or TRIM5α SPRY
domain mutants that failed to inhibit SIVmac infection altered
the anti-SIVmac activity of CV1-TRIM5α. Human T cell line
MT4 cells were first infected with an SeV expressing CV1-
TRIM5α-tag and an SeVexpressing HSC-F-TRIM5α-tag, CV1-
60tag, CV1-delete-tag, HSC-F-delete-tag, or HSC-F +60tag,
incubated at 37 °C for 9 h, and then challenged with SIVmac239.
As shown in Fig. 1C, HSC-F-TRIM5α and CV1-60tag strongly
interfered with the anti-SIVmac activity of CV1-TRIM5α-tag.
The HSC-F-TRIM5α and CV1-60tag shared the 17-amino-acid
region of the HSC-F-TRIM5α SPRY domain and lacked the
CV1-specific 20-amino-acid duplication.
Contrary to our expectation, however, the CV1-delete-tag
and HSC-F-delete-tag, which failed to restrict SIVmac infection,
also failed to show the dominant-negative effect on anti-SIVmac
activity of CV1-TRIM5α-tag. Both of these mutant TRIM5αs
lacked the CV1-specific 20 amino-acid duplication but sharedthe 17-amino-acid region of the SPRY domain with the parental
CV1-TRIM5α. These results indicated that the ability of
TRIM5α to interfere with the anti-SIVmac activity of CV1-
TRIM5α was not only determined by its lack of restriction
activity against SIVmac. On the other hand, the HSC-F +60-tag
that inhibited SIVmac infection (Fig. 1B) did not interfere with
the restricting activity of CV1-TRIM5α-tag (Fig. 1C).
The levels of expression of those TRIM5αs were comparable
to each other (Fig. 1D lanes 1 to 5). Co-expression of CV1-
TRIM5α-tag did not alter the levels of expression of those
TRIM5αs (Fig. 1D, lanes 6 to 9). Conversely, the expression
levels of co-expressed CV1-TRIM5α-tag were also comparable
to each other (Fig. 1D, lanes 6 to 9).
A single round replication assay further confirmed the above
findings since co-expression of HSC-F-TRIM5α-tag or CV1-
60tag with CV1-TRIM5α-tag strongly interfered with anti-
SIVmac activity of CV1-TRIM5α-tag in CD4 negative HeLa
cells infected with vesicular stomatitis virus G-protein-pseudo-
typed SIVmac. Similarly, co-expression of CV1-delete-tag or
HSC-F-delete-tag with CV1-TRIM5α-tag did not interfere with
anti-SIVmac activity of CV1-TRIM5α-tag in a single round
replication assay (Fig. 2).
To assess whether or not these parental and chimeric
TRIM5αs really form hetero-oligomer, we performed immuno-
precipitation followed by Western blot analysis. We used ham-
ster kidney cell line TK-ts13 since it lacks primate TRIM5α
proteins. Cells were transfected with plasmid expressing various
HA-tagged version of chimeric TRIM5αs with a plasmid ex-
pressing myc-tagged version of CV1-TRIM5α. Sixty hours after
transfection, cells were lysed and TRIM5α proteins were immu-
noprecipitated with an antibody against HA. Resultant immu-
noprecipitants were subjected to Western blot analysis using
Fig. 3. Co-precipitation analysis of TRIM5α multimerization. For lanes 1 to 5,
hamster TK-ts13 cells were transiently co-transfected with a plasmid expressing
myc-tagged version of CV1-TRIM5α protein along with a plasmid expressing
an indicated HA-tagged TRIM5α. For lanes 6 to 11, cells were co-transfected
with an empty vector pcDNA3.1(−) along with a plasmid expressing an
indicated HA-tagged version of TRIM5α protein. Cell lysates were subjected for
immunoprecipitation by using an anti-HA antibody, and immunoprecipitates
were analyzed by Western blot by using antibody indicated. Closed triangles
denote TRIM5α proteins. Open triangles denote non-specifically reacted
protein.
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myc-tagged CV1-TRIM5αs were clearly co-immunoprecipi-
tated with HA-tagged version of CV1-, CV1-60, CV1-delete,
HSC-F, and HSC-F-delete TRIM5α proteins. These results
suggested that not only homologous but also heterologous oli-
gomers of TRIM5α examined above were formed in cells. A
heat shock protein inhibitor geldanamysin was reported to in-
hibit cytoplasmic body formation (Song et al., 2005). Addition
of 10 μMof geldanamysin in the culture media did not affect the
homo- or hetero-oligomerization of TRIM5αs (data not shown),
excluding the possibility that co-immunoprecipitation of CV-
TRIM5α with various TRIM5αs was caused by non-specific
aggregation of TRIM5α proteins in cytoplasmic bodies. There-
fore, the lack of the dominant-negative effect of chimeric
TRIM5α on anti-SIVmac activity of CV-1-TRIM5αwas not due
to a lack of oligomer formation between CV1 and chimeric
TRIM5αs.
Discussion
It was first reported that rhesus monkey TRIM5γ, a splice
variant lacking SPRY (B30.2) domain, had a dominant-negative
effect on HIV-1 restriction activity of rhesus monkey TRIM5α
(Stremlau et al., 2004). Subsequently, Berthoux et al. reported
that expression of rhesus monkey TRIM5α or owl monkey
TRIM5-cypA in human cells interferes with the anti-N-MLV
activity of endogenous human TRIM5α (Berthoux et al., 2005).
Perez-Caballero et al. reported that truncated human TRIM5α
proteins lacking the B30.2/SPRY domain form heteromultimers
with full-length human TRIM5α and are dominant inhibitors of
its N-MLV restriction (Perez-Caballero et al., 2005). Further-
more, Mishe et al. clearly showed that the TRIM5α protein
oligomerizes into trimers and proposed that trimerizationpotentially allows SPRY domain to interact with threefold
pseudosymmetrical structures on retroviral capsids (Mishe et al.,
2005).
In the present study, we demonstrated that the HSC-F-
TRIM5α had a dominant-negative effect on the anti-SIVmac
activity of CV1-TRIM5α. A chimeric TRIM5α carrying the
HSC-F-derived 17-amino-acid residues without the CV1-
specific 20-amino-acid duplication (CV1-60tag) also showed a
dominant-negative effect. These results emphasized the impor-
tance of the 17-amino-acid residue as well as the 20-amino-acid
duplication of CV1-TRIM5α in the restriction of SIVmac
infection and further suggested that the oligomeric structure of
SPRY domain is required for the restriction of SIVmac infection
by CV1-TRIM5α. Nevertheless, two mutant TRIM5αs carrying
the CV1-derived 17-amino-acid region without the 20-amino-
acid duplication (HSC-F-delete-tag and CV1-delete-tag) did not
show the dominant-negative effect, even though all the chimeric
andmutant TRIM5αs mentioned above failed to restrict SIVmac
as the parental HSC-F-TRIM5α-tag and CV1-60tag. Immuno-
precipitation and Western blot analysis of cells co-transfected
with myc-tagged version of CV1-TRIM5α and HA-tagged
versions of those chimeric andmutant TRIM5αs confirmed their
heterologous oligomers formation regardless of the presence or
absence of a dominant-negative effect on anti-SIVmac activity
of CV1-TRIM5α. These results indicated that it is not necessary
for all the TRIM5α molecules in one trimer to carry the 20-
amino-acid duplication for anti-SIVmac activity. It is possible
that tight interaction between the viral capsid and all three
TRIM5α molecules in one trimer may not be necessary for res-
triction activity. Alternatively, a certain capsid modification,
which is not observed on all the capsid molecules in the virions,
may mimic the CV1-specific 20-amino-acid duplication.
It is expected that four types of trimer form in heterologous
TRIM5α expressing cells. In cells expressing equal amount of
CV1-TRIM5α and HSC-F-TRIM5α, (1) one out of eight trimers
would be a homo-trimer of CV1-TRIM5α molecules, (2) three
out of eight trimers would be hetero-trimers composed of two
molecules of CV1-TRIM5α and one molecule of HSC-F-
TRIM5α, (3) three out of eight trimers would be hetero-trimers
composed of one molecules of CV1-TRIM5α and two mole-
cules of HSC-F-TRIM5α, and (4) one out of eight trimers would
be a homo-trimer of HSC-F-TRIM5α molecules. The CV1-
TRIM5α homo-trimer would completely inhibit SIVmac infec-
tion, whereas HSC-F-TRIM5α homo-trimer would fail to inhibit
SIVmac. We showed that cells expressing CV1-TRIM5α-tag
and HSC-F-TRIM5α-tag produced approximately two third of
p27 antigen of the cells expressing HSC-F-TRIM5α-tag alone
(Fig. 2). The slight reduction of p27 antigen production is most
likely caused by the presence of at least one out of eight TRIM5α
trimers possessing anti-SIVmac activity. Conversely, cells co-
expressing CV1-delete-tag or HSC-F-delete-tag with CV1-
TRIM5α-tag showed slight but significant increase in p27
production upon SIVmac infection compared with those expres-
sing CV1-TRIM5α-tag alone. This is again explained by the
presence of one out of eight TRIM5α trimers lacking anti-
SIVmac activity. Therefore, determination of the exact numbers
of molecules carrying the 20-amino-acid duplication within an
162 E.E. Nakayama et al. / Virology 350 (2006) 158–163active TRIM5α trimer against SIVmac would be important to
help understand the precise molecular mechanisms of anti-viral
activity of TRIM5α.
Materials and methods
Construction of chimeric TRIM5α expressing plasmid
Construction of parental and chimeric TRIM5αs carrying an
HA tag (YPYDVPDYAA) at their C-termini was described
previously (Nakayama et al., 2005). Briefly, cloned CV1-
TRIM5α and HSC-F-TRIM5α cDNAs in pcDNA3.1 were used
as templates for PCR amplification with a primer containing a
nucleotide sequence corresponding to the HA-tag fused with the
C-terminal portion of TRIM5α. The C-terminal portion of
TRIM5α fused with the HA-tag (BamHI to NotI) and the N-
terminal portion of TRIM5α (NotI to BamHI) were assembled in
a pCEP4 vector (Invitrogen). To generate chimeric TRIM5α
HSC-F +60tag, the 182 bp SphI–BamHI fragment of HSC-F-
TRIM5α-tag was replaced with the corresponding 242 bp SphI–
BamHI fragment of CV1-TRIM5α in the background of HSC-F-
TRIM5α-tag. Conversely, the 242 bp SphI–BamHI fragment of
CV1-TRIM5α was replaced with the 182 bp SphI–BamHI
fragment of HSC-F-TRIM5α-tag in the background of CV1-
TRIM5α-tag to generate CV1-60tag. CV1-delete-tag, which
possessed the 3′ proximal 98 bp of the SphI–BamHI fragment of
HSC-F-TRIM5α in the background of CV1-TRIM5α-tag, was
generated by a PCR-based mutagenesis of CV1-TRIM5α-tag.
The SphI–BamHI fragment of HSC-F-TRIM5α was replaced
with the corresponding fragment of CV1-delete-tag to generate
HSC-F-delete-tag.
SIVmac infection
Construction of recombinant SeVs expressing various TRI-
M5αs was described previously (Nakayama et al., 2005). For
CD4-dependent infection assays, 2.5 × 105 MT4 cells were
infected with SeV expressing CV1-TRIM5α-tag, HSC-F-
TRIM5α-tag, CV1-60tag, HSC-F-delete-tag, CV1-delete-tag,
or HSC-F +60tag at a multiplicity of infection of five plaque-
forming units per cell for each SeVand incubated at 37 °C for 9 h.
Cells were then super-infected with 30 ng of p27 of SIVmac239.
The culture supernatants were collected periodically, and the
level of p27 was measured with a RETROtek antigen ELISA kit
(ZeptoMetrix). For a single round replication assay, CD4-nega-
tive HeLa cells were infected with SeV expressing various
TRIM5αs at a multiplicity of infection of 5 plaque-forming unit
per cell. Cells were then super-infected with 30 ng of p27 of
vesicular stomatitis virus G-protein-pseudotyped SIVmac239.
Immunoprecipitation and Western blot analysis
For co-immunoprecipitation analysis, we constructed CV1-
TRIM5α carrying myc-tag (EQKLISEEDL) at its C-termini and
cloned into pcDNA3.1(−) vector (Invitrogen). Hamster kidney
TK-ts13 cells were co-transfected with 10 μg of a plasmid
expressing myc-tagged version of CV1-TRIM5α and 10 μg of aplasmid expressing HA-tagged TRIM5α by using calcium
phosphate method. Sixty hours after transfection, cells were
harvested and lysed in lysis buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Nonident P40, 0.5% sodium deoxycholate).
TRIM5α proteins in the lysates were precipitated with anti-HA
High Affinity rat monoclonal antibody (Roche) using a Protein
G Immunoprecipitation Kit (Roche). Precipitated materials were
subjected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). Proteins in the gel were then electro-
nically transferred to a membrane (Immobilon, Millipore). Blots
were blocked and probed with anti-myc mouse monoclonal
antibody (9B11, Cell Signaling) or anti-HA High Affinity rat
monoclonal antibody (Roche) overnight at 4 °C. Blots were
then incubated with peroxidase-conjugated anti-mouse IgG
(Kirkegaard and Perry Laboratories) or anti-rat IgG (American
Qualex), and bound antibodies were visualized with a Chemi-
lumi-one chemiluminescent kit (Nacalai tesque, Kyoto, Japan).
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